Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28446465.
- Also identified by DOI 10.1158/0008-5472.CAN-16-2938 and PMC identifier 5505499.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunometabolism is emerging as a critical determinant of cancer pathophysiology. In this study, we explored the contributions of macrophage-expressed lactate dehydrogenase-A (LDH-A) to tumor formation in a K-Ras murine model of lung carcinoma. Myeloid-specific deletion of LDH-A promoted accumulation of macrophages with a CD86<sup>high</sup> and MCP-1<sup>high</sup> M1-like phenotype that suppressed tumor growth. This phenotypic effect was accompanied by reduced VEGF expression and angiogenesis, diminished numbers of PD-L1<sup>+</sup> cancer cells, increased numbers of CD3<sup>+</sup> T cells, and activation status of CD8<sup>+</sup> T cells. Furthermore, it was associated with more pronounced antitumor T-cell immunity via induction of IL17 and IFNγ-producing CD8<sup>+</sup> T (Tc17 and Tc1) cells, likely via suppression of lactate-driven PD-L1 expression. Our results suggest that expressions of LDH-A and lactate by macrophage in the tumor microenvironment are major drivers of T-cell immunosuppression, strongly supporting the concept of targeting stromal LDH-A as an effective strategy to blunt tumoral immune escape. <i>Cancer Res; 77(13); 3632-43. ©2017 AACR</i>.
Medical subject headings
- L-Lactate Dehydrogenase
- Lung Neoplasms
- Myeloid Cells